Foghorn Therapeutics Valuation Multiples

Foghorn Therapeutics Overview

About Foghorn Therapeutics

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Founded

2015

HQ

Employees

112

Website

foghorntx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $31M

EBITDA: ($89M)

EV

$164M

Valuation Multiples

Multiples.vc

Start free trial

Foghorn Therapeutics Financials

Foghorn Therapeutics reported last 12-month revenue of $31M and negative EBITDA of ($89M).

In the same LTM period, Foghorn Therapeutics generated $31M in gross profit, ($89M) in EBITDA losses, and had net loss of ($76M).

Foghorn Therapeutics P&L

In the most recent fiscal year, Foghorn Therapeutics reported revenue of $31M and EBITDA of ($79M).

Foghorn Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Foghorn Therapeutics Stock Performance

Foghorn Therapeutics has current market cap of $281M, and enterprise value of $164M.

Foghorn Therapeutics' stock price is $4.79.

Foghorn Therapeutics Valuation Multiples

Foghorn Therapeutics trades at 5.2x EV/Revenue multiple, and (1.8x) EV/EBITDA.

Foghorn Therapeutics Financial Valuation Multiples

As of April 10, 2026, Foghorn Therapeutics has market cap of $281M and EV of $164M.

Equity research analysts estimate Foghorn Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Foghorn Therapeutics has a P/E ratio of (3.7x).

Foghorn Therapeutics Margins & Growth Rates

Foghorn Therapeutics' revenue in the last 12 month grew by 13%.

Foghorn Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.0M for the same period.

Foghorn Therapeutics' rule of 40 is (313%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Foghorn Therapeutics' rule of X is (303%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Foghorn Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Foghorn Therapeutics M&A Activity

Foghorn Therapeutics acquired XXX companies to date.

Last acquisition by Foghorn Therapeutics was on XXXXXXXX, XXXXX. Foghorn Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Foghorn Therapeutics Investment Activity

Foghorn Therapeutics invested in XXX companies to date.

Foghorn Therapeutics made its latest investment on XXXXXXXX, XXXXX. Foghorn Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).